Breakthrough drug combo may replace plasma exchange for rare blood disease
NCT ID NCT05468320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called caplacizumab, combined with immune-suppressing medicines, could treat a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) without the usual plasma exchange procedure. Fifty-one adults aged 18 to 80 took part. The goal was to see if this drug-only approach could bring the disease under control and avoid the need for plasma exchange.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center Site Number : 8400022
Durham, North Carolina, 27710-4000, United States
-
Investigational Site Number : 0560003
Yvoir, 5530, Belgium
-
Investigational Site Number : 1240001
Toronto, Ontario, M5B 1W8, Canada
-
Investigational Site Number : 2030001
Brno, 62500, Czechia
-
Investigational Site Number : 2030003
Prague, 128 00, Czechia
-
Investigational Site Number : 2500001
Paris, 75012, France
-
Investigational Site Number : 2500002
Bois-Guillaume, 76230, France
-
Investigational Site Number : 2500003
Paris, 75010, France
-
Investigational Site Number : 2500005
Lille, 59037, France
-
Investigational Site Number : 2760001
Frankfurt am Main, 60590, Germany
-
Investigational Site Number : 2760002
Cologne, 50937, Germany
-
Investigational Site Number : 2760004
Hanover, 30625, Germany
-
Investigational Site Number : 2760006
Berlin, 10117, Germany
-
Investigational Site Number : 3800001
Milan, Lombardy, 20122, Italy
-
Investigational Site Number : 3800003
Avellino, Campania, 83100, Italy
-
Investigational Site Number : 3800004
Vicenza, 36100, Italy
-
Investigational Site Number : 3800005
Verona, 37134, Italy
-
Investigational Site Number : 3800006
Genova, 16132, Italy
-
Investigational Site Number : 3920001
Iruma-gun, Saitama, 350-0495, Japan
-
Investigational Site Number : 3920003
Kurashiki-shi, Okayama-ken, 710-8602, Japan
-
Investigational Site Number : 5280002
Amersfoort, 3818 TZ, Netherlands
-
Investigational Site Number : 7240001
Madrid / Madrid, Madrid, Comunidad de, 28007, Spain
-
Investigational Site Number : 8260001
London, London, City of, NW1 2PG, United Kingdom
-
Investigational Site Number : 8260002
Liverpool, L7 8XP, United Kingdom
-
Johns Hopkins University- Site Number : 8400007
Baltimore, Maryland, 21287, United States
-
The Ohio State University Comprehensive Cancer Center - Site Number : 8400001
Columbus, Ohio, 43210, United States
-
University of Alabama- Site Number : 8400011
Birmingham, Alabama, 35233, United States